# Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

> **NCT00003465** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 60 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00003465
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** —
- **Final completion:** 2001-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003465, "Temozolomide in Treating Patients With Anaplastic Oligodendroglioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*